Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta-Regression Analysis.

José M Rodriguez-Valadez Malak Tahsin Umesh Masharani Meyeon Park M G Myriam Hunink Joseph Yeboah Lihua LiEllerie WeberAsem BerkalievaLuuk AvezaatWendy B Max Kirsten E Fleischmann Bart S Ferket

Published in: Journal of the American Heart Association (2024)

We confirmed increased efficacy findings for major adverse cardiovascular events with reduction in glycated hemoglobin for GLP1-RAs. Further research is needed on the potential loss of cardiovascular benefits with increased weight loss and hematocrit for SGLT2i.

Keyphrases

cardiovascular events
weight loss
cardiovascular disease
coronary artery disease
type diabetes
glycemic control
human health
bariatric surgery
roux en y gastric bypass
risk assessment
gastric bypass
combination therapy
skeletal muscle
red blood cell
body mass index
insulin resistance
smoking cessation